Antineoplastic drug monitoring.

The ability to monitor biologically significant levels of antineoplastic drugs in patients' plasma is rapidly expanding. The expanded application of therapeutic drug monitoring to the clinical practice of oncology will require a better understanding of the relationship between drug levels, toxicity, and therapeutic benefit in particular patient populations.